title: Neuroprotective effects of NKN on focal cerebral ischemia in rats.
abstract: OBJECTIVE
  NKN reduces brain edema, neuronal death and neurological deficits in rats     after cerebral ischemia. In the present study, we investigated whether NKN was     effective on brain injury in cerebral ischemia rats.
  
  
  METHODS
  The     middle cerebral artery occlusion (MCAO) model was used to produce experimental     cerebral ischemia in adult male Wistar rats. The activity of SOD and     concentration of MDA were determined. We also examined the efficacy of NKN on     neurological deficit scores, expression of N-methyl-D-aspartate receptor and     endothelin-1 mRNA in brain of focal cerebral ischemia rats.
  
  
  RESULTS
  The results     show that NKN significantly increased the activity of SOD, decreased the     concentration of MDA, decreased neurological deficit scores, inhibited the     expression of N-methyl-D-aspartate receptor and endothelin-1 mRNA in brain of     focal cerebral ischemia rats.
  
  
  CONCLUSIONS
  The results implied NKN could protect     brain against injury caused by cerebral ischemia.
authors.affiliation: Xinxiang Medical University, College of Pharmacy, Xinxiang, China. ychg58@sina.com
authors.forename: Chunguang
authors.initials: C
authors.lastname: Yang
authors.forename: Hongwei
authors.initials: H
authors.lastname: Wang
authors.forename: Shiling
authors.initials: S
authors.lastname: Zhang
authors.forename: Yanna
authors.initials: Y
authors.lastname: Cheng
authors.forename: Jing
authors.initials: J
authors.lastname: Sun
mesh_terms: D045784:Abietanes / Q000627:therapeutic use; D000098:Acetophenones / Q000627:therapeutic use; D000818:Animals; D001565:Benzoates / Q000627:therapeutic use; D002545:Brain Ischemia / Q000188:drug therapy* / Q000473:pathology; D001952:Bridged-Ring Compounds / Q000627:therapeutic use; D004338:Drug Combinations; D019332:Endothelin-1 / Q000096:biosynthesis; D005960:Glucosides / Q000627:therapeutic use; D007150:Immunohistochemistry; D017403:In Situ Hybridization; D020244:Infarction, Middle Cerebral Artery / Q000473:pathology; D008297:Male; D008315:Malondialdehyde / Q000378:metabolism; D009460:Neurologic Examination; D009474:Neurons / Q000473:pathology; D018696:Neuroprotective Agents / Q000627:therapeutic use*; D011719:Pyrazines / Q000627:therapeutic use; D051381:Rats; D017208:Rats, Wistar; D016194:Receptors, N-Methyl-D-Aspartate / Q000378:metabolism; D020521:Stroke / Q000473:pathology; D013482:Superoxide Dismutase / Q000378:metabolism
chemical_list: D045784:Abietanes; D000098:Acetophenones; D001565:Benzoates; D001952:Bridged-Ring Compounds; D004338:Drug Combinations; D019332:Endothelin-1; D005960:Glucosides; D018696:Neuroprotective Agents; D011719:Pyrazines; D016194:Receptors, N-Methyl-D-Aspartate; C572199:naokangning; D008315:Malondialdehyde; D013482:Superoxide Dismutase